相关实验视频
Updated: Jul 16, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
500
肝脏病学家的肥胖管理-要做什么,如何做,为什么?
Kymberly D Watt1, Sonali Paul2, Mohammad Qasim Khan3
1Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Hepatology (Baltimore, Md.)
|September 19, 2023
概括
肥胖严重影响肝脏健康和肝病诊所的患者护理. 这篇评论详细介绍了肝病学家和胃肠病学家如何管理肥胖症作为一种关键的并发症.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内部医学 内部医学
- 临床营养学 临床营养学
背景情况:
- 肥胖是一种普遍的疾病,在肝病学临床环境中经常遇到.
- 肥胖显著影响慢性肝病 (CLD) 的进展,并影响患者的治疗策略.
- 越来越需要专门的方法来解决肝脏疾病护理中的肥胖问题.
研究的目的:
- 在肝病学背景下提供关于肥胖管理的全面概述.
- 概述肝脏病学家和胃肠病学家在管理肥胖和肝脏疾病患者方面的实用策略.
- 强调将肥胖护理纳入常规肝病学实践的重要性.
主要方法:
- 对有关肥胖和肝脏疾病的当前文献进行系统审查.
- 分析临床指导方针和专家建议,以控制肝病学中的肥胖症.
- 综合基于证据的患者评估和治疗方法.
主要成果:
- 肥胖是各种肝病的发展和进展的关键因素,包括非酒精性脂肪肝病 (NAFLD).
- 有效的体重管理策略可以导致肝脏参数和患者整体结果的显著改善.
- 为了获得最佳的结果,可能需要涉及营养学家,内分泌学家和外科医生的多学科方法.
结论:
- 肝病学家和胃肠病学家必须积极参与肥胖的管理.
- 将肥胖管理纳入肝脏病学实践对于改善患者护理和治疗结果至关重要.
- 解决这种并发症需要采取主动和基于证据的方法.
相关概念视频
Obesity
534
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
534
Chronic Pancreatitis II: Collaborative Care
113
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
113
Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Diabetes: Management and Pharmacotherapy
309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Esophageal Varices-II: Clinical Features and Management
94
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
94
Diseases of the Liver and Gallbladder
621
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
621

